Skip to main content

Evidence-based management of dyslipidemias in women

Current Atherosclerosis Reports volume 5, pages 379–385 (2003)Cite this article

Abstract

Women and men are both susceptible to coronary artery disease (CAD). The predictors or risk factors of CAD are qualitatively identical, although low-density lipoprotein is less of a predictor, and high-density lipoprotein and triglycerides are more predictive in women. Diabetes is also a stronger predictor of CAD in women. Lowering of low-density lipoprotein cholesterol is as important in women as in men, as demonstrated in clinical trials. Hormone replacement therapy has not been proven in trials to prevent CAD and may even promote it in some patients. The role of emerging risk factors in CAD prevention is still unclear in either gender. Trials now in progress should clarify this issue.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Bass KM, Newschaffer CJ, Klag MJ, Bush TL: Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993, 153:2209–2016.

    PubMed  Article  CAS  Google Scholar 

  2. LaRosa JC: Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997, 157:961–968.

    PubMed  Article  CAS  Google Scholar 

  3. LaRosa JC, He J, Vupputuri S: Effects of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 1999, 282:2340–2346.

    PubMed  Article  CAS  Google Scholar 

  4. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.

    Article  Google Scholar 

  5. Sandkamp M, Assmann G: Lipoprotein(a) in PRO-CAM participants and young myocardial infarction survivors. In Lipoprotein(a). Edited by Scanu AM. New York: Academic Press; 1990:205–209.

    Google Scholar 

  6. Brewer HB: Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels. In Lipoprotein(a). Edited by Scanu AM. New York: Academic Press; 1990:211–220.

    Google Scholar 

  7. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease—application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.

    PubMed  Article  Google Scholar 

  8. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, et al.: Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001, 85:619–625.

    PubMed  CAS  Google Scholar 

  9. Tan KC, Chow WS, Tam SC, et al.: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasolidation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002, 87:563–568.

    PubMed  Article  CAS  Google Scholar 

  10. Plenge JK, Hernandez TL, Weil KM, et al.: Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002, 106:1447–1452.

    PubMed  Article  CAS  Google Scholar 

  11. Walsh BW, Paul S, Wild RA, et al.: The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metal 2000, 85:214–218.

    Article  CAS  Google Scholar 

  12. Schnyder G, Roffi M, Pin R, et al.: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001, 345:1593–1600.

    PubMed  Article  CAS  Google Scholar 

  13. LaRosa JC: Future clinical trials of lipid-lowering drugs. In Lipids and Atherosclerosis Annual. Edited by Gaw A, Shepherd J. In press.

  14. Krolewski AS, Warram JH, Valsania P, et al.: Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991, 90:56S-61S.

    PubMed  Article  CAS  Google Scholar 

  15. Soler JT, Folsom AR, Kushi LH, et al.: Association of body fat distribution with plasma lipids, lipoproteins, apolipoproteins A-1 and B in postmenopausal women. J Clin Epidemiol 1988, 41:1075–1081.

    PubMed  Article  CAS  Google Scholar 

  16. Lapidus L, Bengtsson C, Larsson B, et al.: Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984, 289:1257–1261.

    PubMed  CAS  Google Scholar 

  17. Grodin JM, Siiteri PK, MacDonald PC: Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973, 36:207–214.

    PubMed  CAS  Article  Google Scholar 

  18. Barnard RJ: Effects of life-style modification on serum lipids. Arch Intern Med 1991, 151:1389–1394.

    PubMed  Article  CAS  Google Scholar 

  19. Bush TL: The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990, 592:263–271.

    PubMed  Article  CAS  Google Scholar 

  20. van der Schouw YT, van der Graaf Y, Steyerberg EW, et al.: Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996, 347:714–718.

    PubMed  Article  Google Scholar 

  21. The PEPI Investigators: Effects of estrogen or estrogen-progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273:199–208.

    Article  Google Scholar 

  22. Adams MR, Register TC, Golden DL, et al.: Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Aterioscler Thromb Vasc Biol 1997, 17:217–221.

    CAS  Google Scholar 

  23. Psaty BM, Heckbert SR, Atkins D, et al.: The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994, 154:1333–1339.

    PubMed  Article  CAS  Google Scholar 

  24. Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613.

    PubMed  Article  CAS  Google Scholar 

  25. Herrington DM, Reboussin DM, Brosnihan KB, et al.: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000, 343:522–529.

    PubMed  Article  CAS  Google Scholar 

  26. Clarke S, Kelleher J, Lloyd-Jones H, et al.: Transdermal hormone replacement therapy for secondary prevention of coronary artery disease in postmenopausal women [abstract]. Eur Heart J 2000, 21:212.

    Google Scholar 

  27. Angerer P, Stork S, Kothny W, et al.: Effect of oral postmenopausal hormone replacement on progression of atherosclerosis. A randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001, 21:262–268.

    PubMed  CAS  Google Scholar 

  28. Viscoli CM, Brass LM, Kernan WN, et al.: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001, 345:1243–1249.

    PubMed  Article  CAS  Google Scholar 

  29. Hodis HN, Mack WJ, Lobo RA, et al., for the Estrogen in the Prevention of Atherosclerosis Trial Research Group: Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 135:939–953.

    PubMed  CAS  Google Scholar 

  30. deKleijn MJ, Bots ML, Bak AA, et al.: Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. Atherosclerosis 1999, 32:195–204.

    CAS  Google Scholar 

  31. Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002, 288:321–333.

    Article  Google Scholar 

  32. The ESPRIT Team: Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002, 360:2001–2008.

    Article  Google Scholar 

  33. Wood D, De Backer G, Faergeman O, et al.: Prevention of coronary heart disease in clinical practice. Eur Heart J 1998, 19:1434–1503.

    Article  Google Scholar 

  34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Article  Google Scholar 

  35. Robins SJ, Collins D, Wittes JT, et al., for the VA-HIT Study Group: Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA 2001, 285:1585–1591.

    PubMed  Article  CAS  Google Scholar 

  36. The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000, 102:21–27.

    Google Scholar 

  37. Mensink RP, Katan MB: Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. Lancet 1987, 8525:122–125.

    Article  Google Scholar 

  38. Masarei JR, Rouse IL, Lynch WJ, et al.: Effects of a lacto-ovo vegetarian diet on serum concentration of cholesterol, triglyceride, HDL-C, HDL2-C, HDL3-C, apoprotein-B, and Lp(a). Am J Clin Nutr 1984, 40:468–478.

    PubMed  CAS  Google Scholar 

  39. Ernst N, Bowen P, Fisher M, et al.: Changes in plasma lipids and lipoproteins after a modified fat diet. Lancet 1980, 1:111–113.

    Article  Google Scholar 

  40. Lokey EA, Tran ZV: Effects of exercise training on serum lipid and lipoprotein concentrations in women: A meta-analysis. Int J Sports Med 1989, 10:424–429.

    PubMed  CAS  Article  Google Scholar 

  41. Hartung GH, Moore CE, Mitchell R, et al.: Relationship of menopausal status and exercise level to HDL cholesterol in women. Exp Aging Res 1984, 10:13–18.

    Google Scholar 

  42. Tanko LB, Bagger YZ, Alexandersen P, et al.: Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 2003, 107:1626–1631.

    PubMed  Article  Google Scholar 

  43. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999, 341:498–511.

    PubMed  Article  CAS  Google Scholar 

  44. Sudhop T, Lutjohann D, Kodal A, et al.: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943–1948.

    PubMed  Article  CAS  Google Scholar 

  45. Gagne C, Gaudet D, Bruckert E, for the Ezetimibe Study Group: Efficacy and safety of ezetimibe co-administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469–2475.

    PubMed  Article  CAS  Google Scholar 

  46. Herrington DM, Klein KP: Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings. Atherosclerosis 2003, 166:203–212.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. The State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, 11203, Brooklyn, NY, USA

    John C. LaRosa MD

Authors
  1. John C. LaRosa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

LaRosa, J.C. Evidence-based management of dyslipidemias in women. Curr Atheroscler Rep 5, 379–385 (2003). https://doi.org/10.1007/s11883-003-0009-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-003-0009-y

Keywords

  • Postmenopausal Woman
  • Statin
  • Homocysteine
  • Hormone Replacement Therapy
  • Ezetimibe